COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

To Evaluate the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients (2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03443804
Recruitment Status : Completed
First Posted : February 23, 2018
Last Update Posted : February 28, 2018
Information provided by (Responsible Party):
Daewon Pharmaceutical Co., Ltd.

Brief Summary:
Evaluate the Efficacy and Safety of DW1401 versus Stillen tab. in Patients with Acute or Chronic Gastritis

Condition or disease Intervention/treatment Phase
Gastritis Acute Gastritis Chronic Drug: Test(DW1401) Drug: Reference(Stillen tab.) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 462 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase 3 Clinical Trial to Evaluated the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients
Actual Study Start Date : July 2014
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Arm Intervention/treatment
Experimental: Test(DW1401)
tid PO, DW1401+Placebo of Stillen tab.
Drug: Test(DW1401)
DW1401+Placebo of Stillen tab.

Active Comparator: Reference(Stillen tab.)
tid PO, Stillen tab.+Placebo of DW1401
Drug: Reference(Stillen tab.)
Stillen tab.+Placebo of DW1401

Primary Outcome Measures :
  1. The efficacy rate on gastroscopy [ Time Frame: 0, week 2 ]

    The efficacy rate is obtained from the following formula using the subject whose erroneous score is improved by 50% or more as compared with before the study drug administration.

    The efficacy rate(%) = (number of effective cases)/(all cases) x 100

    Effective case is determined by the grade change of erosion. A case in which the grade changes from 4 to 2 or 1, from 3 to 1, or from 2 to 1 is judged as an effective case.

Secondary Outcome Measures :
  1. Cure rate on gastroscopy [ Time Frame: 0, week 2 ]

    Judging from the gastroscopic examination as normal (no erosion), the cure rate is obtained as follows.

    Cure rate(%) = (number of cures(no erosion))/(all cases) x 100

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who were diagnosed with acute or chronic gastritis in a gastroscopy performed within 7 days prior to administration of this trial.
  • At least one or more erosions have been identified on gastroscopy.
  • Patients who decided to voluntarily participate in this trial and agreed in writing.

Exclusion Criteria:

  • Patients who can not undergo gastroscopy
  • Peptic ulcer (except scarring) and reflux esophagitis
  • Patients who have had gastric acid suppression surgery or stomach/esophagus surgery (except for simple perforation surgery and appendectomy)
  • Patients with a history of gastrointestinal malignancies
  • Zollinger-Ellison syndrome patients
  • Patient with spontaneous coagulation disorder
  • Patients with an allergic or hypersensitive response to a study drug
  • Patients with a potential pregnancy.
  • Patients who had clinically significant abnormalities in the screening test. (ALT, AST, BUN, Serum creatinine is more than twice the upper limit)
  • Pregnant and lactating women
  • Those currently taking other study drugs
  • patients who were judged to be ineligible for the trial by the principle investigator and the person in charge.
Layout table for additonal information
Responsible Party: Daewon Pharmaceutical Co., Ltd. Identifier: NCT03443804    
Other Study ID Numbers: DW1401-302
First Posted: February 23, 2018    Key Record Dates
Last Update Posted: February 28, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no plan for IPD.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases